Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.

Date publication

novembre 2015

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe

Tous les auteurs :
Albiges L, Kube U, Eymard JC, Schmidinger M, Bamias A, Kelkouli N, Mraz B, Florini S, Guderian G, Cattaneo A, Bergmann L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26276039

Résumé

To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, therapeutic use, Carcinoma, Renal Cell, drug therapy, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Europe, Everolimus, adverse effects, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, drug therapy, Male, Middle Aged, Nephrectomy, Risk Factors, Time Factors, Treatment Outcome, Vascular Endothelial Growth Factor A, antagonists & inhibitors, Young Adult

Référence

Eur. J. Cancer. 2015 Nov;51(16):2368-74